Urogen Pharma Ltd
NASDAQ:URGN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.64
19.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Urogen Pharma Ltd
Wall Street
Price Targets
URGN Price Targets Summary
Urogen Pharma Ltd
According to Wall Street analysts, the average 1-year price target for
URGN
is 40.73 USD
with a low forecast of 22.22 USD and a high forecast of 67.2 USD.
URGN Last Price Targets
Urogen Pharma Ltd
The latest public price target was made on Oct 14, 2024 by
Jason Kolbert
from
EF Hutton
,
who expects
URGN
stock to
rise by 134%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Jason Kolbert
EF Hutton
|
25
USD
Upside 134% |
2 months ago
Oct 14, 2024
|
EF Hutton Starts UroGen Pharma (URGN) at Buy
StreetInsider
|
Stephen Richardson
Evercore ISI
|
46
USD
Upside 330% |
6 months ago
Jun 14, 2024
|
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga
|
Paul Choi
Goldman Sachs
|
22
USD
Upside 106% |
6 months ago
Jun 14, 2024
|
Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
StreetInsider
|
Leland Gershell
Oppenheimer
|
40
USD
Upside 274% |
6 months ago
Jun 14, 2024
|
UroGen Pharma price target raised to $40 from $32 at Oppenheimer
TheFly
|
|
Raghuram Selvaraju
H.C. Wainwright
|
60
USD
Upside 461% |
6 months ago
Jun 14, 2024
|
UroGen Pharma price target raised to $60 from $54 at H.C. Wainwright
TheFly
|
|
Leland Gershell
Oppenheimer
|
32
USD
Upside 199% |
7 months ago
May 14, 2024
|
UroGen Pharma (URGN) PT Lowered to $32 at Oppenheimer
StreetInsider
|
|
Leland Gershell
Oppenheimer
|
34
USD
Upside 218% |
9 months ago
Mar 15, 2024
|
UroGen Pharma (URGN) PT Lowered to $34 at Oppenheimer
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is URGN's stock price target?
Price Target
40.73
USD
According to Wall Street analysts, the average 1-year price target for
URGN
is 40.73 USD
with a low forecast of 22.22 USD and a high forecast of 67.2 USD.
What is Urogen Pharma Ltd's Revenue forecast?
Projected CAGR
57%
The
compound annual growth rate
of Urogen Pharma Ltd's revenue for the next 4 years is
57%.
You don't have any saved screeners yet
